Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal first quarter ended June 30 amounted to ¥14.92 per share, a decline of 61.5% from ¥38.80 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥59.4 million, a decrease of 61.5% from ¥154.4 million in the prior-year period.
The normalized profit margin fell to 1.4% from 3.8% in the year-earlier period.
Total revenue came to ¥4.13 billion, compared with ¥4.09 billion in the prior-year period, and total operating expenses rose on an annual basis to ¥4.04 billion from ¥3.85 billion.
Reported net income declined 63.7% year over year to ¥53.0 million, or ¥13.32 per share, from ¥146.0 million, or ¥36.69 per share.
As of Aug. 8, US$1 was equivalent to ¥101.85.
